SMMT Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT) is expected to report earnings on October 22, 2026, after the market close. The consensus earnings estimate is a loss of $0.28 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.7% since its last earnings release on July 23, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.
Sector
Healthcare
Industry
Biotechnology